For many countries with ageing populations, dementia presents major challenges: from the provision and costs of social care to the burden of appraising novel medical technologies targeting the dementia-care market. Insurers and reinsurers are not immune from such challenges; improving dementia outcomes could affect mortality rates in our elderly populations, affecting annuities and changing the balance of premiums and payments on protection products.
Insurers are favouring funded re as it helps firms manage the market and longevity risks associated with writing bulk purchase annuity (BPA) business by reducing capital charges and therefore making PRT deals more competitive.
Unsurprisingly, given its growth and potential for capital optimisation, UK regulators have been carefully watching the increased use of funded re. In June 2023, the Prudential Regulatory Authority (PRA) sent a “Dear CRO’ letter to heads of risk at UK life insurers.
The letter outlined the regulator’s two main concerns from a sectoral review which it had carried out.
“One of the key risks arising in funded re is that firms recapture sub-optimal portfolios with depressed values and with limited ability to be transformed effectively to the firms’ preferred portfolio,” the PRA letter said.
Related Posts
New Report Suggests Life Settlement Market Poised for Long-Term Expansion
Structural tailwinds provide positive outlook but complexities still need to be managed.
The Structural Decision for Setting Up a Life Settlement Vehicle in Ireland
Two different structuring options provide flexibility for life settlement investors.
Litigation Update: U.S. Bank National Association v. Pacific Life Insurance Company
A recent decision by Judge Thomas J. Lo of the Superior Court of California, Orange…
Q&A: Beat Hess, Managing Partner, AA-Partners
Beat Hess, Managing Partner of AA-Partners, explains why he thinks that Distributed to Paid-In is…
